Fig. 5: Protection of neutralizing antibody from convalescents of COVID-19 against the circulating variants of SARS-CoV-2.
a, Neutralizing antibody titres (indicated as ID50) against the WT, Alpha, Beta, Gamma, Delta, Lambda and Mu variants measured at early (between 15 and 60 d.a.o., N = 22) and late (over 360 d.a.o., N = 26) convalescent phases. Black dotted lines indicate the limit of detection for ID50. The line and error bar represent the geometric mean titres (GMTs) and the standard deviation for the GMTs. Statistical significance was determined using a two-sided Mann–Whitney U-test. *P < 0.05, **P < 0.01, ***P < 0.001. P values for the early phase: WT vs Alpha, 0.0028; WT vs Beta, <0.001; WT vs Delta, <0.001; WT vs Gamma, 0.0543; WT vs Lambda, 0.0108; WT vs Mu, <0.001. P values for the late phase: WT vs Alpha, 0.4318; WT vs Beta, <0.001; WT vs Delta, <0.001; WT vs Gamma, 0.3281; WT vs Lambda, <0.001; WT vs Mu, <0.001. Specimens with ID50 <20 were assigned a value of 10. GMTs and fold changes (FCs) of ID50 between the variants and the wild-type SARS-CoV-2 are shown at the bottom. b, Representative neutralizing activities against different variants of the paired samples from the same patients in both the early and the late convalescent phases. Patient numbers, MN titres and follow-up days are shown at the top of each graph.
